<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>383-NORFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>383-NORFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de points. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>383-NORFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia. </COMMENT>
</INTERACTION>
</INTERACTIONS>
